Keio Innovation Initiative

Developer of radiopharmaceuticals intended to offer treatment of cancer. The company engages in the research and development of therapeutic and diagnostic drugs for cancer using 64Cu which is a radioisotope of copper, enabling doctors to provide cancer treatments to the patients.

Aeterlink is a developer of innovative wireless power transfer technology aimed at creating a digital landscape devoid of wires. The company specializes in applying its advanced technology across various sectors, including factory automation, robotics, smart homes, and healthcare. By enabling wireless power transmission over distances, Aeterlink's solutions enhance efficiency and sustainability while improving safety by eliminating the hazards associated with traditional wiring. Their practical level technologies facilitate greater flexibility in device placement and operation, contributing to a more connected and streamlined environment across multiple industries.

JiMED is a company focused on developing wireless embedded brain-computer interface (BCI) systems that facilitate the reading of brain activity. It offers a wireless implantable BCI system that utilizes an implanted device combined with artificial intelligence to interpret neural signals. This innovative technology enables individuals, particularly those suffering from ALS, to communicate more effectively and improve their quality of life by allowing them to operate the device through thought alone.

Neusignal Therapeutics is a medical company focused on developing small molecule drugs aimed at treating dementia and psychiatric disorders. The company is engaged in research and development initiatives designed to address various central nervous system diseases, striving to provide therapeutic solutions for patients suffering from brain health issues. By targeting these challenging conditions, Neusignal Therapeutics aims to improve the quality of life for individuals affected by cognitive and psychiatric challenges.

BlueWX is a technology company specializing in advanced weather forecast services. It leverages current research and artificial intelligence to enhance the precision of weather predictions, particularly for aviation. The company's services include detailed forecasts for flight routes, aiming to improve safety and operational efficiency for airlines and other aviation-related businesses. Additionally, BlueWX caters to industries that rely on accurate weather information for their operations.

DigitalArchi is a manufacturing company that specializes in producing sustainable architectural components. It uses large-scale 3D printing technology to create interior and exterior panels, as well as concrete formwork, from recycled plastic. This process not only helps reduce waste but also addresses labor shortages in the construction industry by enabling businesses to fabricate forms for concrete construction more efficiently.

Optieum Biotechnologies Inc. is a pre-clinical stage biotechnology company focused on developing innovative antibody-based therapies for cancer treatment. Utilizing its proprietary Eumbody System™, the company creates and detects single-chain variable fragment (scFv) product candidates that specifically target and modulate immune cell functions for oncology applications. By enhancing the proliferation capacity and longevity of single-chain variable CAR-T cells, Optieum aims to improve patient responses to advanced tumors while minimizing adverse effects. The company's commitment lies in delivering transformative therapies to patients suffering from severe diseases.

Japan Carbon Cycle Lab is a technology company that focuses on the research and development of CO2 capture and recycling techniques.

elleThermo specializes in developing Semiconductor-Sensitised Thermal Cells (STCs), a technology designed to convert unused waste heat above room temperature into electricity.

Nihon Agri, Inc. is a Tokyo-based company established in 2016 that specializes in the export and coordination of Japanese agricultural products. The company addresses the challenges faced by Japanese farmers, such as pricing, communication, and logistics, which hinder the growth of agricultural exports. By providing comprehensive services that include in-house farm production guidance, branding, and the import of agricultural materials, Nihon Agri aims to facilitate the export of high-quality Japanese produce to international markets. The company is dedicated to bridging the gap between Japanese farmers and global consumers, helping to satisfy the increasing demand for Japanese agricultural products abroad.

Aeterlink is a developer of innovative wireless power transfer technology aimed at creating a digital landscape devoid of wires. The company specializes in applying its advanced technology across various sectors, including factory automation, robotics, smart homes, and healthcare. By enabling wireless power transmission over distances, Aeterlink's solutions enhance efficiency and sustainability while improving safety by eliminating the hazards associated with traditional wiring. Their practical level technologies facilitate greater flexibility in device placement and operation, contributing to a more connected and streamlined environment across multiple industries.

PURMX is a pharmaceutical company focused on developing RNA nucleic acid medicines aimed at treating intractable diseases, particularly malignant pleural mesothelioma. The company specializes in creating innovative nucleic acid drugs that utilize small ribonucleic acid to address deficiencies in cells. By providing targeted therapies for cancer treatment, PURMX aims to improve patient outcomes and support healthcare professionals in their efforts to manage complex medical conditions.

Red Arrow Therapeutics develops a healthcare technology that replaces conventional cancer treatments. The company focuses on next‑generation therapies that enhance drug potency while reducing toxicity, aiming to improve outcomes across various tumor models, both as monotherapy and in combination with immune checkpoint inhibitors.

Newmo is a technology company that specializes in sustainable local public transportation. It develops a ride-sharing service platform, enabling drivers to work flexibly using their free time, and providing passengers with a safe, secure, and comfortable user experience.

Founded in Tokyo, Japan in 2008, Axelspace designs, manufactures, and sells micro-satellites and related components for earth observation. Its primary projects include GRUS, Hodoyoshi-1, and UNIFORM, aiming to provide global daily monitoring at low cost.

Hedgehog MedTech is a medical company specializing in digital therapeutics (DTx), which are programmable medical devices approved by pharmaceutical standards to assist in patient health management through mobile applications. The firm has developed a health application specifically aimed at treating headaches. This application utilizes a system that identifies and enhances behavioral patterns to alleviate symptoms. By delivering cognitive-behavioral therapy via the smartphone app, Hedgehog MedTech effectively connects users' daily lives with their medical care, particularly in the treatment of migraines.

Nanofiber Quantum Technologies is a research and manufacturing company focused on developing innovative hardware for quantum communications. The company specializes in creating quantum computers that utilize nanofibers and advanced engineering techniques. Its expertise encompasses quantum cryptography, quantum communications, and various technologies associated with quantum science aimed at practical applications. By integrating quantum computers into quantum communication networks, Nanofiber Quantum Technologies seeks to advance the field of quantum science and enhance secure communication methods for a range of clients.

Metagen Therapeutics is a drug discovery and development company that leverages microbiome science, with a focus on the gut microbiome to advance pharmaceuticals, healthcare solutions, functional foods, and academic research. Formed as a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., the company aims to unlock microbiome-based therapies and collaborative approaches across industry and academia.

Heartseed Inc. is a Tokyo-based biotechnology company founded in 2015, focused on developing myocardial regeneration medicine utilizing induced pluripotent stem (iPS) cells. The company's mission is to advance treatments for heart disease through regenerative medicine, specifically targeting advanced heart failure with iPS cell-derived cardiomyocyte replacement therapy. Heartseed aims to enable the clinical application of its innovative therapies to improve outcomes for patients suffering from heart conditions.

Metagen Therapeutics is a drug discovery and development company that leverages microbiome science, with a focus on the gut microbiome to advance pharmaceuticals, healthcare solutions, functional foods, and academic research. Formed as a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., the company aims to unlock microbiome-based therapies and collaborative approaches across industry and academia.

Hedgehog MedTech is a medical company specializing in digital therapeutics (DTx), which are programmable medical devices approved by pharmaceutical standards to assist in patient health management through mobile applications. The firm has developed a health application specifically aimed at treating headaches. This application utilizes a system that identifies and enhances behavioral patterns to alleviate symptoms. By delivering cognitive-behavioral therapy via the smartphone app, Hedgehog MedTech effectively connects users' daily lives with their medical care, particularly in the treatment of migraines.

Metagen Therapeutics is a drug discovery and development company that leverages microbiome science, with a focus on the gut microbiome to advance pharmaceuticals, healthcare solutions, functional foods, and academic research. Formed as a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., the company aims to unlock microbiome-based therapies and collaborative approaches across industry and academia.

LIFESCAPES is a research and manufacturing company specializing in brain-computer interface equipment, particularly for neurorehabilitation. The company's technology focuses on aiding stroke patients by enhancing brain plasticity, which allows individuals to overcome limitations and improve their quality of life. LIFESCAPES' devices are designed to extract and analyze brain-wave data in real-time, monitoring the activity of the functional compensation circuits in stroke patients. This innovative approach enables healthcare professionals to assist patients in regaining movement and addressing movement disorders, ultimately facilitating a more normal and fulfilling life for those affected.

K Pharma Inc is a pharmaceutical company focused on research, development, manufacturing, and marketing of innovative medical products, particularly in the field of neuro regenerative medicine. The company leverages induced pluripotent stem (iPS) cell technology to advance treatments for neurological conditions, including cerebral infarction and spinal cord injury. By integrating cutting-edge drug discovery methods with a commitment to developing effective medical solutions, K Pharma aims to address unmet needs in the healthcare sector. The company's efforts encompass the entire spectrum of pharmaceutical operations, from initial research through to the final product.

FingerVision is a company that specializes in the development of advanced sensing devices and robotic hands, aimed at enhancing the functionality and versatility of robots and machines. By integrating visual and haptic technology derived from academic research, FingerVision addresses various social challenges while improving automation in industries. The company's innovations enable robots to perform tasks that traditionally required human intervention, particularly in pick-and-place operations, thereby increasing efficiency and reducing labor costs. Through its cutting-edge technology, FingerVision seeks to expand the applications of robotics across different sectors.

Alivexis is a private preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates targeting high-value disease conditions. The company leverages advanced computational drug discovery techniques and unique biological insights to expedite the development of new medicines. Its international team comprises experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical, biotechnology, and technology firms. By focusing on innovative approaches, Alivexis aims to enhance biotechnological research and improve the efficiency of delivering essential medicines to patients with unmet medical needs.

Cellusion is a regenerative medicine company developing induced pluripotent stem cell-derived corneal endothelial cells for the treatment of bullous keratopathy. The company focuses on research, development, manufacturing, and commercial supply of corneal endothelial cell substitutes for transplantation to restore corneal function and vision. Originating from Keio University, Cellusion aims to enable scalable, cell-based therapies by cultivating corneal endothelial cells from iPS sources and delivering them for surgical transplantation. Based in Tokyo, Japan, the company emphasizes advancing regenerative ophthalmology through cell-based therapies that offer less invasive treatment options for patients with endothelial corneal disease.

Luxonus is a medical device manufacturing company that specializes in developing innovative imaging technology using photoacoustic methods. The company's core product is a diagnostic device that utilizes optical ultrasonic technology to capture ultra-high-resolution three-dimensional images of blood vessels and lymphatic vessels. This imaging approach allows for safe and non-invasive detection and diagnosis of diseases, providing healthcare professionals with a comprehensive understanding of disease onset, healing processes, and health conditions before and after illness. By combining light and ultrasonic waves, Luxonus aims to enhance medical imaging capabilities and improve patient outcomes.

Grace Imaging is a company focused on developing advanced fatigue measurement services through the use of lactic acid sensing in sweat and MRI technologies. It has created a device specifically designed to measure lactic acid concentration in sweat, which aids in the analysis and evaluation of fatigue. By utilizing sweat lactate sensors, Grace Imaging enables users to assess exercise load and monitor changes in muscle condition, providing valuable insights into physical performance and recovery.

Heartseed Inc. is a Tokyo-based biotechnology company founded in 2015, focused on developing myocardial regeneration medicine utilizing induced pluripotent stem (iPS) cells. The company's mission is to advance treatments for heart disease through regenerative medicine, specifically targeting advanced heart failure with iPS cell-derived cardiomyocyte replacement therapy. Heartseed aims to enable the clinical application of its innovative therapies to improve outcomes for patients suffering from heart conditions.

Metagen Therapeutics is a drug discovery and development company that leverages microbiome science, with a focus on the gut microbiome to advance pharmaceuticals, healthcare solutions, functional foods, and academic research. Formed as a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., the company aims to unlock microbiome-based therapies and collaborative approaches across industry and academia.

B dot Medical specializes in developing ultra-compact proton beam cancer therapy equipment. Their system utilizes radiotherapy to precisely target tumors while minimizing damage to surrounding tissues, enabling more affordable proton cancer therapy.

Connect Japan is developing services that connect people.

AdipoSeeds develops a platelet-making system that generates platelets from mesenchymal stem cells without complex and costly gene transfer. The company aims to address global platelet shortages by enabling a future in which platelet-related treatments are cheaply and safely provided, supported by a new blood supply system. Its technology also leverages adipose-derived materials to produce fat-derived platelets for blood products and wound care medicine, positioning AdipoSeeds to serve biotechnology clients seeking innovative platelet-based solutions.

Skygate Technologies Inc., founded in 2020 and based in Tokyo, Japan, specializes in designing and developing a cloud ground station platform that facilitates communication between satellites and the Earth. The company aims to democratize space-to-Earth communication, thereby fostering the growth of the NewSpace ecosystem. Its offerings include a ground station as a service, optimized for low Earth orbit satellites, which automatically acquires and tracks satellites. By integrating advanced features such as a unified antenna specification and a software radio, Skygate Technologies enables clients to establish cloud-native communication infrastructure. The company's motto, "Make Space accessible on the Web," reflects its commitment to making satellite data more accessible and integrated into web architecture.

Alivexis is a private preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates targeting high-value disease conditions. The company leverages advanced computational drug discovery techniques and unique biological insights to expedite the development of new medicines. Its international team comprises experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical, biotechnology, and technology firms. By focusing on innovative approaches, Alivexis aims to enhance biotechnological research and improve the efficiency of delivering essential medicines to patients with unmet medical needs.

BONX Inc. is a Tokyo-based company that specializes in the design and development of wearable communication devices for outdoor sports enthusiasts. Established in 2014, BONX has created the BONX Grip, a Bluetooth earpiece designed to withstand water and shock, allowing athletes engaged in activities such as snowboarding, cycling, stand-up paddleboarding, and fishing to communicate seamlessly. The device supports group conversations, enabling users to stay connected with friends while participating in leisure and sporting activities. BONX sells its products online, catering to a niche market of outdoor sports participants seeking reliable communication solutions.

APB specializes in the research, development, manufacture, and sales of lithium-ion batteries. It uses polymer instead of metal for current collectors and coats active materials with dedicated polymer materials to enhance battery performance.

Kringle Pharma is a Japanese biopharmaceutical company focused on the research and development of hepatocyte growth factor (HGF)–based protein medicines and NK4 therapies. The company aims to leverage HGF’s regenerative properties and NK4’s antiangiogenic activity to address organ repair and cancer indications. Its pipeline includes recombinant human HGF for acute renal failure, spinal cord injury, and CNS diseases, as well as recombinant NK4 and NK4 gene therapies for cancer. Founded in 2001, the company operates in the Japanese market.

Cellusion is a regenerative medicine company developing induced pluripotent stem cell-derived corneal endothelial cells for the treatment of bullous keratopathy. The company focuses on research, development, manufacturing, and commercial supply of corneal endothelial cell substitutes for transplantation to restore corneal function and vision. Originating from Keio University, Cellusion aims to enable scalable, cell-based therapies by cultivating corneal endothelial cells from iPS sources and delivering them for surgical transplantation. Based in Tokyo, Japan, the company emphasizes advancing regenerative ophthalmology through cell-based therapies that offer less invasive treatment options for patients with endothelial corneal disease.

Luxonus is a medical device manufacturing company that specializes in developing innovative imaging technology using photoacoustic methods. The company's core product is a diagnostic device that utilizes optical ultrasonic technology to capture ultra-high-resolution three-dimensional images of blood vessels and lymphatic vessels. This imaging approach allows for safe and non-invasive detection and diagnosis of diseases, providing healthcare professionals with a comprehensive understanding of disease onset, healing processes, and health conditions before and after illness. By combining light and ultrasonic waves, Luxonus aims to enhance medical imaging capabilities and improve patient outcomes.

Synspective specializes in developing and operating small synthetic aperture radar (SAR) satellites, providing SAR data and remote monitoring services. It caters to urban design, infrastructure, energy, insurance, finance sectors, and government agencies.

Motion Lib, Inc. is a Japanese company specializing in the development of haptic technology aimed at enhancing collaboration between humans and robots. Founded in 2016 and based in Kawasaki, the company was previously known as Undou Sekkei Kenkyuusho Limited before rebranding in April 2017. Motion Lib creates advanced chips that estimate and calculate the repulsive force of objects being touched by robots, using the load force applied to the motor. This innovative technology enables robots to engage more effectively in various tasks, thereby expanding their operational capabilities and contributing to increased productivity across different sectors.

Instalimb, Inc. is a pioneering company based in Tokyo, Japan, specializing in the development of low-cost 3D printed prosthetics and orthotics. Leveraging advanced 3D-CAD, 3D printing, and machine learning technologies, Instalimb aims to revolutionize the prosthetics industry by significantly reducing production costs and delivery times. The company utilizes an innovative algorithm that enhances design efficiency, allowing for the creation of customized prosthetic devices tailored to individual needs. This cutting-edge approach not only makes prosthetics more accessible to amputees but also represents a significant advancement in the field of assistive technology. As the world's first business dedicated to 3D printed prostheses, Instalimb is committed to improving the quality of life for individuals requiring these essential devices.

Xenodata Lab, Co., Ltd., founded in 2012 and based in Tokyo, Japan, specializes in artificial intelligence-driven data analysis. The company develops a platform that transforms unstructured data from financial reports into structured, table-format data, enhancing accuracy and accessibility for users. By focusing on economic forecasts and financial document analysis, Xenodata Lab enables businesses to effectively interpret and utilize information following financial results announcements. The company aims to advance the financial industry through innovative technology and the efficient processing of data, emphasizing the potential of AI to enhance human decision-making in this sector.

Luxonus is a medical device manufacturing company that specializes in developing innovative imaging technology using photoacoustic methods. The company's core product is a diagnostic device that utilizes optical ultrasonic technology to capture ultra-high-resolution three-dimensional images of blood vessels and lymphatic vessels. This imaging approach allows for safe and non-invasive detection and diagnosis of diseases, providing healthcare professionals with a comprehensive understanding of disease onset, healing processes, and health conditions before and after illness. By combining light and ultrasonic waves, Luxonus aims to enhance medical imaging capabilities and improve patient outcomes.

Himuka AM Pharma Corp. is a pharmaceutical company based in Miyazaki City, Japan, established in February 2017. The company focuses on the research, development, and discovery of drug candidates derived from adrenomedullin, a bioactive peptide initially identified at the University of Miyazaki. Himuka AM Pharma aims to create innovative therapies that target mucosal healing and clinical remission, addressing significant unmet medical needs in healthcare. Through its specialized approach to developing adrenomedullin derivatives, the company seeks to contribute meaningfully to advancements in medical treatments.

BONX Inc. is a Tokyo-based company that specializes in the design and development of wearable communication devices for outdoor sports enthusiasts. Established in 2014, BONX has created the BONX Grip, a Bluetooth earpiece designed to withstand water and shock, allowing athletes engaged in activities such as snowboarding, cycling, stand-up paddleboarding, and fishing to communicate seamlessly. The device supports group conversations, enabling users to stay connected with friends while participating in leisure and sporting activities. BONX sells its products online, catering to a niche market of outdoor sports participants seeking reliable communication solutions.

CureApp, Inc. is a Tokyo-based digital health startup founded in 2014, specializing in the development of mobile applications aimed at treating various diseases. The company is recognized for its innovative approach to healthcare, particularly with its nicotine addiction treatment app launched in February 2015, which was developed in collaboration with the Division of Pulmonary Medicine at Keio University’s School of Medicine. CureApp’s platform not only promotes clinical trials but also focuses on providing real-time, personalized guidance for lifestyle diseases through a cloud-based system that analyzes daily activity logs. This enables patients to manage their conditions more effectively, addressing health issues that are often overlooked by traditional medications and devices.

Tsubota Laboratory Inc focuses on research and development aimed at preventing and treating various eye conditions, including myopia, dry eye, and presbyopia. The company is dedicated to creating evidence-based solutions and develops both pharmaceuticals and medical devices to address these eye diseases and related systemic disorders. Through its innovative approach, Tsubota Laboratory strives to improve eye health and enhance the quality of life for individuals affected by these conditions.

Institution for a Global Society is a people analytics company that specializes in providing innovative assessment solutions to educational institutions and businesses. The organization focuses on the identification, recruitment, and development of human capital through its various offerings, which include GROW Academy, DxGROW, Ai GROW, and GROW360. By leveraging predictive analytics, the company serves a diverse clientele, including multinational corporations, government agencies, and international institutions. Committed to ethical technology use, Institution for a Global Society aims to foster a sustainable learning environment that supports lifelong development for individuals across various sectors.

IDAC Theranostics, Inc. is a biotechnology company based in Tokyo, Japan, established in 2012. It focuses on the research, development, and production of pharmaceutical products aimed at treating cancer, graft-versus-host disease (GVHD), inflammatory diseases, and other conditions. The company specializes in creating drug therapies for diseases that traditionally require only symptomatic treatment. IDAC Theranostics collaborates with Japanese academic institutions, pharmaceutical companies, and international organizations to advance its research and development efforts, striving to provide innovative solutions for patients with unmet medical needs.

Motion Lib, Inc. is a Japanese company specializing in the development of haptic technology aimed at enhancing collaboration between humans and robots. Founded in 2016 and based in Kawasaki, the company was previously known as Undou Sekkei Kenkyuusho Limited before rebranding in April 2017. Motion Lib creates advanced chips that estimate and calculate the repulsive force of objects being touched by robots, using the load force applied to the motor. This innovative technology enables robots to engage more effectively in various tasks, thereby expanding their operational capabilities and contributing to increased productivity across different sectors.

Generic Solution Corporation, established in 2006 and headquartered in Tokyo, Japan, specializes in software distribution services, focusing on data analytics and artificial intelligence. The company offers GS8 software, which is designed for information retrieval and machine learning, and provides distributed computing services, data model design, and data analysis. By employing large-scale data analytic techniques, Generic Solution aims to help clients organize and analyze extensive information, ultimately enabling them to set profit targets and achieve measurable outcomes. The company's commitment to delivering generic solutions enhances its clients' competitiveness in the market.

BONX Inc. is a Tokyo-based company that specializes in the design and development of wearable communication devices for outdoor sports enthusiasts. Established in 2014, BONX has created the BONX Grip, a Bluetooth earpiece designed to withstand water and shock, allowing athletes engaged in activities such as snowboarding, cycling, stand-up paddleboarding, and fishing to communicate seamlessly. The device supports group conversations, enabling users to stay connected with friends while participating in leisure and sporting activities. BONX sells its products online, catering to a niche market of outdoor sports participants seeking reliable communication solutions.

CureApp, Inc. is a Tokyo-based digital health startup founded in 2014, specializing in the development of mobile applications aimed at treating various diseases. The company is recognized for its innovative approach to healthcare, particularly with its nicotine addiction treatment app launched in February 2015, which was developed in collaboration with the Division of Pulmonary Medicine at Keio University’s School of Medicine. CureApp’s platform not only promotes clinical trials but also focuses on providing real-time, personalized guidance for lifestyle diseases through a cloud-based system that analyzes daily activity logs. This enables patients to manage their conditions more effectively, addressing health issues that are often overlooked by traditional medications and devices.

Quan Inc., founded in 2011 and based in Tokyo, Japan, specializes in developing character-driven content for smartphone applications and web platforms. The company offers a diverse portfolio of over 500 characters, including Betakkuma, Sugar Cubs, and Business Fish, which are utilized in various messaging applications and social games, primarily targeting markets in Japan and Southeast Asia. In addition to character development, Quan Inc. provides global content distribution services and creates illustrations and stamps for chat apps. The company also engages in public relations and advertising, offering services such as market research, translation, and game management to enhance user engagement and promote its content effectively.

AdipoSeeds develops a platelet-making system that generates platelets from mesenchymal stem cells without complex and costly gene transfer. The company aims to address global platelet shortages by enabling a future in which platelet-related treatments are cheaply and safely provided, supported by a new blood supply system. Its technology also leverages adipose-derived materials to produce fat-derived platelets for blood products and wound care medicine, positioning AdipoSeeds to serve biotechnology clients seeking innovative platelet-based solutions.

Kringle Pharma is a Japanese biopharmaceutical company focused on the research and development of hepatocyte growth factor (HGF)–based protein medicines and NK4 therapies. The company aims to leverage HGF’s regenerative properties and NK4’s antiangiogenic activity to address organ repair and cancer indications. Its pipeline includes recombinant human HGF for acute renal failure, spinal cord injury, and CNS diseases, as well as recombinant NK4 and NK4 gene therapies for cancer. Founded in 2001, the company operates in the Japanese market.

SENSY Inc., founded in November 2011 and based in Tokyo, Japan, specializes in artificial intelligence technology that focuses on understanding human sensibilities. The company develops a personal AI system that learns the unique sensitivities of individual users, facilitating transformative experiences across various aspects of daily life. SENSY's technology leverages natural language processing to analyze diverse data sources, including images, text, music, and user interactions. This capability allows businesses to implement personalized marketing strategies by predicting customer preferences, visit timings, and responses to promotional efforts. SENSY provides both business-to-consumer and business-to-business services, as well as support for launching new business-related initiatives.